Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
BOSTON SCIENTIFIC CORP
High uncertainty: The valuation methods show significant disagreement (>100% spread). Treat the range as a rough guide rather than a precise estimate.
Bear Case (25th pct.)
-32.0% vs price
Base Case (Median)
-0.8% vs price
Bull Case (75th pct.)
36.7% vs price
◇ = Current price | | Bear | Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $61.49 | 43.8% | High (40%) |
| PE Comparable | $55.48 | 29.7% | Medium (25%) |
| Growth Trajectory DCF | $91.26 | 113.4% | Medium (20%) |
| Graham Number | $30.27 | -29.2% | Medium (40%) |
| EV/EBITDA | $27.85 | -34.9% | Medium (20%) |
| EV/FCF | $42.42 | -0.8% | Medium (20%) |
| Earnings Power Value | $27.51 | -35.7% | Medium (50%) |
Based on 7 out of 7 methods, BSX appears fairly valued at the current price of $42.77. The base case fair value of $42.42 implies 0.8% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.